Patent · US Active

HIV consensus envelope sequences and methods for using the same

US9376471B2 · kind B2 · utility

5Cited by
48References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 23, 2013
Grant dateJun 28, 2016
Priority date
Expiry dateDec 31, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2770/24234
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.